interferon related developmental regulator 2Genealiases: IFNRP · SKMc15 · SM15
Q-omics provides the consensus-scored IFRD2 profile across patient tissues and cancer cell-line models. IFRD2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, IFRD2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, IFRD2 RNA expression shows 19,040 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where IFRD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFRD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFRD2 survival associations across molecular data types. IFRD2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFRD2 RNA expression–survival associations across cancer types. High IFRD2 expression shows unfavorable associations in ACC, CESC, KIRC, LGG and LIHC, but favorable associations in READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for IFRD2 RNA expression.
This table summarizes IFRD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for IFRD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFRD2 shows higher tumor expression in COAD, LIHC, KIRP, LUAD, STAD and CHOL. The COAD box plot shows higher IFRD2 RNA expression in tumor versus normal tissue (log2 FC = +1.807, t-test p < 0.001).
This table shows molecular features associated with IFRD2 in patient tissues and cancer cell lines. In patient samples, IFRD2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, IFRD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
